Leber's hereditary optic neuropathy with 3460 mitochondrial DNA mutation. by Hwang, Jeong-Min et al.
INTRODUCTION
Leber’ s hereditary optic neuropathy (LHON) is a mater-
nally inherited disease characterized by acute or subacute
loss of the central vision primarily in young men (1). Mito-
chondrial inheritance was first confirmed in 1988 by Wal-
lace et al. with the identification of a mitochondrial DNA
point mutation at nucleotide position 11778 in the NADH
dehydrogenase subunit 4 gene in nine pedigrees with a clini-
cal diagnosis of LHON (2). A second mutation at nucleotide
position 3460 was identified in three pedigrees without the
11778 mutation by Huoponen et al. in 1991 (3). LHON is
associated with three different point mutations of mitochon-
drial DNA (mtDNA) affecting nucleotide positions 3460
(3-5), 11778 (2), and 14484 (6). These mutations are esti-
mated to account for 8-25%, 50-60%, and 10% of LHON
pedigrees respectively (3-7). The incidence of each mutation
is reported to be race-dependent (3-7).
Since the first identification of the 11778 mutation in
Korean patients in 1995 (8), 60 patients with a 11778 muta-
tion (9) and 12 patients with a 14484 mutation have hith-
erto been identified (10). LHON is now recognized as one
of the most common causes of optic neuropathy in young
males (11). However, among the known primary muta-
tions, 3460 mutation has not been confirmed in Koreans.
CASE REPORT
A 35-yr-old man complained of visual disturbance in his
left eye 10 months ago, followed by a decline in his right vi-
sion three months ago. The visual loss did not accompany
any ocular or orbital pain. His medical history was unremark-
able, and had no history of smoking or consuming alcohol.
He did not admit to elicit drug use, nor had any visually sym-
ptomatic family members.
Corrected visual acuity was finger count OU, and color vi-
sion was 0/14 OU by Ishihara color test. Temporal pallor of
both optic discs was observed. Goldmann perimetry exami-
nation revealed bilateral cecocentral scotoma (Fig. 1).
DNA analysis
MtDNA analysis was undertaken for four LHON muta-
tions (at np 11778, np 3460, np 14484, and np 15257). DNA
was extracted from peripheral white blood cells using the
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Leber's Hereditary Optic Neuropathy with 3460 Mitochondrial DNA
Mutation
Leber’ s hereditary optic neuropathy (LHON) is a maternally transmitted disease
causing acute or subacute, bilateral optic atrophy mainly in young men. It is found
to be a mitochondrial disorder with the primary mitochondrial DNA (mtDNA) muta-
tions at 11778, 3460, and 14484. The incidence of each mutation is reported to
be race-dependent. Point mutations at mtDNA nucleotide position 11778 and
14484 have been reported in Korean patients with LHON, however there has
been no report of mtDNA mutation at nucleotide position 3460. Molecular genet-
ic analyses at four primary sites (11778, 14484, 15257, and 3460) of mitochon-
drial DNA using the polymerase chain reaction, restriction enzyme digestion, and
direct sequencing were performed in a 35-yr-old man with severe visual loss. A
point mutation in the mtDNA at nucleotide position 3460 was identified and a con-
version of a single alanine to a threonine was confirmed. To our knowledge, this
is the first report confirming mtDNA mutation at nucleotide position 3460 in Kore-
an patients with LHON. Detailed molecular analyses would be very helpful for the
correct diagnosis of optic neuropathy of unknown etiology and for genetic coun-
seling. 
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standard method. Polymerase chain reaction amplifications
and restriction digestion of the target mtDNA sequences
were performed using modifications of previously reported
protocols (12). The mtDNA region bracketing the 3460
mutation was amplified with PCR using the following pri-
mers; forward: -TTCAAATTCCTCCCTGTACG, reverse:
-CCACAAGCTTGGCTACTGCTCGCAGTG, and the
PCR product was digested with BsaHI (New England Bio-
labs, MA, U.S.A.) (Fig. 2A). Verification of the 3460 muta-
tion in the patient who lost the BsaHI site was carried out by
direct sequencing using a Thermo Sequenase radiolabeled
terminator cycle sequencing kit (Amersham, Buckingham-
shire, U.K.) and 6% polyacrylamide sequencing gels (Fig.
2B).
DISCUSSION
Huoponen et al. found a point mutation at mtDNA posi-
tion 3460 coding for subunit 1 of complex I in three indepen-
Fig. 2. (A) Restriction analysis of the PCR product amplified mtDNA around the np3460 area from a normal person (N) and the patient
with LHON (P), showing a 620 bp band of BsaHI site loss in the patient due to MTND1*LHON3460A, M: molecular marker. (B) Sequenc-
ing result of mtDNA around the np 3460 area in the patient with MTND1*LHON3460A, showing C to T mutation in the antisense strand
and G to A mutation in the sense strand.
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Fig. 1. Visual field testing. A cecocentral scotoma was detected in the right (A) and left (B) eyes.
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dent Finnish families with LHON (3). Guanine is replaced
by adenine and this converts the 52nd codon of the ND1 pro-
tein from alanine to threonine. To date, the 3460 mutation
is observed only in LHON and thus its presence deserves to
be a rational basis of the diagnosis of LHON (3, 4). Since
1995, none of over 150 control subjects or 74 patients posi-
tive for the 11778 or 14484 mutation had tested positive for
the 3460 mutation (9-11).
The frequency of the 3460 mutation among LHON pedi-
grees without the 11778 mutation ranges from 13% (13) to
50% (six of 12) in a series performed in the United Kingdom
and Australia (4). Another study of 10 Finnish pedigrees
without the 11778 mutation identified three families (30%)
with the 3460 mutation (3). These differences in the frequen-
cy of the mutation may reflect true population variability,
or they may be simply due to sampling error related to the
relatively small number of patients examined. The three large
series have combined a total of 74 pedigrees without the
11778 mutation, of which 18 (24%) pedigrees were tested
positive for the 3460 mutation (3-5). In Asians, the incidence
of mutations at 3460, 11778, and 14484 were reported to be
4%, 87%, and 9%, respectively among 80 Japanese LHON
pedigrees (14).
The patients with the 3460 mutation have a higher inci-
dence of visual recovery, a higher percentage of pedigrees with
more than one affected family member, and a greater frequen-
cy of tobacco and alcohol abuse than the patients with the
11778 mutation (5). The difference in visual prognosis of
these two mutations and the need for the modification of
possible risk factors provide added significance to genetic
testing for LHON.
Of clinical importance is the fact that the visual prognosis
differs according to the mutations. The rate of visual recovery
with the 3460 mutation was reported to be 20% (5), which
is much higher than the 4% with the 11778 mutation (15),
and lower than 37-58% with the 14484 mutation (6, 10,
16). However, other series did not show any significant dif-
ference in visual outcome between the 11778 and 3460 muta-
tion groups (17). As for the present case, visual acuity did
not improve. However, our patient had only 10 months or
less of follow-up and may yet recover vision.
The percentage of family with more than one visually sym-
ptomatic family member has been reported to be higher in
pedigrees with the 3460 mutation (78%) (3-5) than in those
with the 11778 mutation (43%) (14). In other words, the
3460 mutation may be more likely to result in visual loss
than the 11778 mutation (5). These findings emphasize the
value of molecular genetic testing in patients with suspected
LHON because of the implications for prognosis with respect
to visual recovery and the potential for risk factor modifica-
tion in patients and their maternal relatives.
To our knowledge, this is the first detailed description on
a Korean LHON patient with the 3460 mutation. The pre-
sent case report demonstrates the possible mitochondrial ge-
netic heterogeneity existing among Korean LHON pedigrees,
and emphasizes the necessity for identifying mutations other
than the 11778 for confirmative diagnosis, appropriate coun-
seling for risk-factor management, visual outcome, and fam-
ily planning.
In conclusion, whenever LHON is clinically suspected, de-
tailed molecular analyses not only for the detection of the
11778 mutation but also for that of the other three primary
mutations should be undertaken. 
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